| NZTA-4008 (New Trial) |
| Meds Used |
Epivir, AZT, Sustiva |
| Tx History |
Antiretroviral naive |
| Trial Length |
48 weeks |
| Viral Load |
>400 |
| T-Cells |
>100 |
| Comments |
Study to determine the efficacy of Epivir once a day ion combination with AZT and Sustiva vs. twice a day. |
| Contact |
Kai Gu, Pacific Oaks Research, (310) 360-8800 |
| ABT-378 (New Trial) |
| Meds Used |
ABT-378 |
| Tx History |
NNRTI-naive and prior use with only one PI |
| Trial Length |
48 weeks |
| Viral Load |
>1,000 |
| T-Cells |
No requirement |
| Comments |
Phase IV study to evaluate ABT-378 in PI-experienced participants |
| Contact |
Kai Gu, Pacific Oaks Research, (310) 360-8800 |
| Norvir-Crixivan Intensification |
| Meds Used |
Norvir/ Crixivan |
| Tx History |
All participants must be on Crixivan, on the same regimen for three months or longer, and Norvir naive |
| Trial Length |
48 weeks |
| Viral Load |
Between 50 and 50,000 |
| T-Cells |
No requirement |
| Comments |
Norvir/Crixivan intensification therapy for HIV-infected individuals. Crixivan will be taken twice daily at elevated doses along with a lower dose of Norvir. |
| Contact |
Jacqui Pitt, R.N., Cedars Sinai, (310) 855-3755; Ruth Pinter, R.N., Beer Medical Group, (323) 937-5151 |
| Resistance |
| Phenotypic Testing |
| Meds Used |
Phenotype test |
| Tx History |
Must have at least six months of prior antiviral therapy |
| Trial Length |
One year |
| Viral Load |
>400 |
| T-Cells |
No requirement |
| Comments |
Randomized study to determine if use of a phenotype resistance assay will improve ability to choose antiretroviral regimens. Participants must have failed one or two PI-containing regimens |
| Contact |
Sadia, Harbor UCLA, (310) 222-5291; Christine MacNaughton, UCLA, (310) 206-6414 |
| Viracept-Combivir + Remune |
| Meds Used |
Viracept, Combivir, Remune |
| Tx History |
Antiretroviral naive |
| Trial Length |
48 weeks |
| Viral Load |
>10,000 |
| T-Cells |
>250 |
| Comments |
Randomized, adjuvant-controlled study to compare the virologic and immunologic effects of HAART plus Remune vs. HAART plus Incomplete Freund's adjuvant |
| Contact |
Corie Castro, AIDS Research Alliance, (310) 358-2429 |
| Zerit Extended Release |
| Meds Used |
Zerit, approved antiretrovirals |
| Tx History |
NRTI-naive |
| Trial Length |
48 weeks |
| Viral Load |
>5,000 |
| T-Cells |
>100 |
| Comments |
Evaluation of the safety and antiviral activity of Zerit extended release vs. immediate release formulations, each as part of potent antiretroviral combination therapy |
| Contact |
Corie Castro, AIDS Research Alliance, (310) 358-2429 |
| ACTG 383/Hepatitis C |
| Meds Used |
This is an observational study, approved antiretrovirals from a co-enrollment of another study |
| Tx History |
Must have a diagnosis of Hepatitis C and HIV, less than 2 weeks of antiretroviral therapy |
| Trial Length |
48 weeks |
| Viral Load |
>2,500 |
| T-Cells |
No requirement |
| Comments |
To determine the dynamics of Hepatitis C virus levels in people with HIV infection whose viral load is reduced to less than 500 copies after 16 weeks of HAART. Participants must be co-enrolled in either ACTG 388 or 384. |
| Contact |
Sally or Mario, Harbor-UCLA, (310) 222-3848; Connie Funk, R.N., USC, (323) 343-8282 |
| ACTG 371 |
| Meds Used |
Combivir, Ziagen, Agenerease |
| Tx History |
Treatment naive |
| Trial Length |
48 weeks of treatment plus follow up |
| Viral Load |
>2,000 within seven days of study entry |
| T-Cells |
No requirement |
| Comments |
Study to evaluate the safety and efficacy of quadruple combination therapy which consists of Combivir, Ziagen and Agenerase in people with Acute HIV infection and people who have recently seroconverted |
| Contact |
Connie Funk, R.N., USC, (323) 343-8282 |
| Metabolic Disorders |
| Amprenavir |
| Meds Used |
Agenerase, Ziagen, Epivir or Zerit |
| Tx History |
PI naive |
| Trial Length |
28 week |
| Viral Load |
No requirement |
| T-Cells |
>100 |
| Comments |
Study looking at the effect of Agenerase on carbohydrate and lipid metabolism. Participants will receive Agenerase twice a day (BID) plus Ziagen (BID) plus Epivir (BID). If individuals have received Epivir in the past they will receive Zerit (BID) |
| Contact |
Hannah Edmondson-Melancon, R.N., USC, (323) 343-8280 |
| Sustiva |
| Meds Used |
Sustiva plus your current antiviral therapy |
| Tx History |
Must be on PI therapy for at least four months, NNRTI naive, abnormal levels of lipids in the blood or a high waist measurement compared to hip measurement |
| Trial Length |
Six months |
| Viral Load |
<50 |
| T-Cells |
No requirement |
| Comments |
Study looking at the effect of substituting Sustiva for PI therapy in individuals at increased risk for cardiovascular complications due to HIV-associated metabolic disorders. Participants will be randomized to remain on current therapy or switch to Sustiva |
| Contact |
Patsy Lopez, USC, (323) 343-8277 |
| L-756423 |
| Meds Used |
L-756423, Crixivan, Zerit, Epivir |
| Tx History |
Less than two weeks prior therapy with antiretrovirals and no prior treatment with PIs or Epivir |
| Trial Length |
48 weeks or longer |
| Viral Load |
>10,000 |
| T-Cells |
>100 |
| Comments |
Study to determine the efficacy of L-756423, a new PI. There will be two groups: Group one will receive L-756423 along with Crixivan, Zerit, and Epivir. Group two will receive the same regimen without L-756423 |
| Contact |
Christine MacNaughton, UCLA, (310) 206-6414 |
| Adefovir |
| Meds Used |
Adefovir |
| Tx History |
Must be on stable HAART for a minimum of 16 weeks prior to screening and no other serious infections requiring antibiotic/antiviral therapy |
| Trial Length |
48 weeks |
| Viral Load |
Between 50 and 400 copies |
| T-Cells |
50 or greater |
| Comments |
Study to measure antiviral activity and safety of adefovir as compared to placebo when added to stable highly active antiretroviral treatment (HAART). Participants will receive $20 for each completed visit |
| Contact |
Gary Aquino, L.V.N., Pacific Oaks Research, (310) 360-8800 |
| Sustiva Combination Therapy |
| Meds Used |
Sustiva |
| Tx History |
NNRTI naive |
| Trial Length |
48 weeks |
| Viral Load |
Must have two consecutive viral load tests under 50 |
| T-Cells |
No requirement |
| Comments |
Randomized study to compare duration of viral suppression of a continued PI plus two NRTIs regimen vs. a Sustiva substitution regimen and to evaluate the safety and tolerability of these regimens |
| Contact |
Kai Gu, R.N., Pacific Oaks Research, (310) 360-8800 |
| BID vs. TID |
| Meds Used |
Retrovir, Crixivan, Rescriptor |
| Tx History |
Naive to 3TC, NNRTIs, PIs, and limited experience with AZT (no more than one month). |
| Trial Length |
32 weeks (with possible extension to 56 weeks) |
| Viral Load |
>20,000 |
| T-Cells |
>50 |
| Comments |
Open label study to evaluate the safety and tolerance of investigational combination therapies when taken twice a day versus three times a day. Participants will receive a $20 transportation stipend for every scheduled visit, once enrolled. |
| Contact |
Doug Bowden, AHF Research Center, (323)913-3953 |
| ACTG 400 |
| Meds Used |
Approved anitretrovirals |
| Tx History |
Naive to Viramune, Rescriptor or Sustiva is allowed. No prior exposure (less than seven days) to Agenerase, Invirase, Crixivan or Norvir is allowed |
| Trial Length |
48 weeks |
| Viral Load |
>1000 |
| T-Cells |
No requirement |
| Comments |
Comparative study of salvage antiretroviral therapies for HIV-infected individuals with evidence of nelfinavir treatment failure as reflected by viral load of more than 1,000 |
| Contact |
Connie Funk, R.N., USC, (323) 343-8282 |
| ACTG 384 |
| Meds Used |
Study includes various combinations of Videx, Retrovir, Zerit, Epivir, Sustiva, Viracept |
| Tx History |
Must have less than seven days prior therapy with any antiretroviral medications |
| Trial Length |
Three years |
| Viral Load |
<500 |
| T-Cells |
No requirement |
| Comments |
Randomized double-blind, six-arm study of PIs and/or NNRTIs in combination with NRTIs in initial therapy of HIV infection |
| Contact |
Christine MacNaughton, UCLA, (310) 206-6414; Miriam, Harbor-UCLA, (310) 222-3848: Connie Olson, USC, (323) 343-8279 |
| Adefovir Expanded Access |
| Meds Used |
Adefovir |
| Tx History |
Individuals who have failed combination therapy with commercially available antiretrovirals and have limited treatment options |
| Trial Length |
Until FDA approved |
| Viral Load |
Must be 30,000 or more (by PCR), or 15,000 or more (by bDNA) within the past two months |
| T-Cells |
Must be 50 or less within the past two months |
| Comments |
See Tx history |
| Contact |
Leanne Onsing, R.N., Lim-Keith Multispecialty Medical Clinics, (323) 964-1440; Marsue Davidson, Kraus Medical Partners, (323) 930-2324 or (800) 860-0700 |
| Immunotherapy |
| Interleukin-2 |
| Meds Used |
Interleukin-2 |
| Tx History |
Stable antiviral therapy of more than three drugs for longer than four months |
| Trial Length |
Five years |
| Viral Load |
<10,000 |
| T-Cells |
>50 and <300 |
| Comments |
Phase III study to evaluate the efficacy of Interleukin-2 (IL-2) in HIV-infected individuals on active antiretroviral therapy with low CD4 counts. Participants will be randomized to receive IL-2 or to a control arm. Compensation provided. |
| Contact |
Petra, Harbor, UCLA, (310) 222-3848 |
| Procaine Hydrochloride |
| Meds Used |
Procaine Hydrochloride plus Videx and Hydroxyurea |
| Tx History |
Participants must have a minimum of eight weeks stable antiretroviral therapy, no active opportunistic infections (OI), and not be currently taking Bactrim |
| Trial Length |
32 weeks |
| Viral Load |
Between 5,000 and 1,000,000 |
| T-Cells |
>100 |
| Comments |
A pharmacokinetic and safety study of Procaine Hydrochloride for the treatment of elevated cortisol levels in HIV-infected individuals. |
| Contact |
Corrie Castro, AIDS Research Alliance, (310) 358-2429 |
| ACTG 325 |
| Meds Used |
Subcutaneous rhIL-12 |
| Tx History |
Must continue current antiretroviral therapy and may not have a serious ongoing OI |
| Trial Length |
Eight weeks |
| Viral Load |
No requirement |
| T-Cells |
<50 |
| Comments |
Phase 1 study to determine the tolerance of a range of multiple subcutaneous rhIL-12 dosing regimens. Participants will receive subcutaneous injections twice a week at UCLA |
| Contact |
Christine MacNaughton, UCLA, (310) 206-6414 |
| Lymphoma |
| REVM10 |
| Meds Used |
Infusion of stem cells with REVm10 |
| Tx History |
Have documented non-Hodgkin's or HIV-related Lymphoma with poor prognosis and at least partial response to a standard chemotherapy regimen |
| Trial Length |
One year, possibly longer |
| Viral Load |
No requirement |
| T-Cells |
>100 |
| Comments |
Open label, single arm phase I/II study to determine the feasibility and safety of infusion of stem cells engineered to contain the REVM10 with high-dose chemotherapy in individuals with HIV-related non-Hodgkin's Lymphoma. Participants will receive chemotherapy. |
| Contact |
Christine MacNaughton, UCLA, (310) 206-6414 |
| CHOP/Rituxan |
| Meds Used |
CHOP chemotherapy and Rituxan |
| Tx History |
No prior chemotherapy |
| Trial Length |
Up to one year |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Phase II study of CHOP chemotherapy and Rituxan in newly diagnosed AIDS-related lymphoma |
| Contact |
Sue Cabriales, Brian Espina, LAC-USC, (323) 226-8270, (323) 865-0371 |
| AMC-008 |
| Meds Used |
Ifosfamide, Etoposide, IL-2, IL-12 |
| Tx History |
Failed one or two chemotherapy treatments |
| Trial Length |
Up to one year |
| Viral Load |
No requirements |
| T-Cells |
No requirements |
| Comments |
Ifosfamide and Etoposide followed by IL-2 versus IL-12 versus observation. A phase II trial of IL-2, IL-12 or no additional therapy following response to Ifosfamide/Etoposide chemotherapy for refractory HIV-related non-Hodgkins lymphoma |
| Contact |
Sue Cabriales, Byron Espina, LAC-USC, (323) 226-8270, (323) 865-0371 |
| PEG-L-Asparaginase |
| Meds Used |
PEG-L-Asparaginase (Onscapar) |
| Tx History |
Refractory lymphoma to any prior chemotherapy |
| Trial Length |
One year |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Phase I dose escalation study of PEG-L-Asparaginase (Onscapar), in the treatment of AIDS-related relapsed or refractory lymphoma. Peg-L-Asaparaginase will be given intramuscularly every two weeks. |
| Contact |
Maria Palmer, PA-C, LAC-USC, (323) 226-4578 |
| Kaposi's Sarcoma |
| AMC 009 |
| Meds Used |
Taxol, Doxil |
| Tx History |
Must be on stable antiretroviral treatment for longer than 14 days prior to the study and have no previous experience with chemotherapy |
| Trial Length |
One year |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Study to determine the efficacy of Taxol vs. Doxil for the treatment of HIV-related advanced KS |
| Contact |
Sue Cabriales, LAC USC/Norris Cancer Hospital, (323) 343 8270 |
| Amifostine |
| Meds Used |
Amifostine, Taxol |
| Tx History |
Participants must have biopsy-proven KS with several measurable KS lesions, and not be taking any other experimental drugs or systemic gancyclovir |
| Trial Length |
18 weeks |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Study to evaluate the short-term effectiveness and safety of amifostine in reducing the risk of low white blood cell counts in individuals being treated with Taxol for KS. Participants will be randomized to receive either amifostine before Taxol or Taxol |
| Contact |
Christine MacNaughton, UCLA, (310) 206-6414 |
| AMC 0013 |
| Meds Used |
Antiangiogenesis compound IM862 |
| Tx History |
Must be stable on antiretrovirals treatment for at least eight weeks, have five or more KS lesions, and not receiving any other KS therapy |
| Trial Length |
Six months to one year |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Phase III, randomized, double blind study of antiangiogenesis compound IM862 for individuals with mucocutaneous KS |
| Contact |
Sue Cabriales, LAC USC/Norris Cancer Hospital, (323) 343-8270 |
| SU4516 |
| Meds Used |
SU4516 |
| Tx History |
Must have at least five KS lesions, no pulmonary KS and at least 21 days rest after prior chemotherapy or radiation. |
| Trial Length |
Four weeks to one year, possibly more |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Phase I study of SU4516 AIDS-related KS Antiangiogenesis Factor. Dose escalation to maximum tolerated dose. Doses are given twice weekly intravenously |
| Contact |
Sue Cabriales, R.N., LAC-USC, (323) 343-8270; Christine MacNaughton, UCLA, (310) 206-6414 |
| AMC 004 |
| Meds Used |
Interferon alpha 2b (IFN-a2b), Norvir, Zerit |
| Tx History |
No concurrent acute OIs |
| Trial Length |
Participants will return for a study visit every 2 weeks for the first eight weeks, and then on a monthly basis |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Randomized study to determine the safety and tolerance of interferon-alpha 2b (IFN-a2b) in combination with Norvir and d4T in HIV-infected individuals with KS. IFN-a2b will be administered subcutaneously once a day |
| Contact |
Christine MacNaughton, UCLA, (310) 206-6414 |
| CMV |
| Ocular Complications |
| Meds Used |
None, this is a follow-up study |
| Tx History |
Participants must have no pre-existing ocular problems |
| Trial Length |
Four years |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
A multicenter study that follows individuals to record the incidents and frequencies of eye complications |
| Contact |
Michael Cornish, Ph.D., Jules Stein Eye Institute-UCLA, (310) 794-5608 |
| CMARC-CMV |
| Meds Used |
None, this is a follow-up study |
| Tx History |
Participants must have a current or past diagnosis of CMV |
| Trial Length |
Six months |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Multicenter study to determine the factors that place individuals at risk for developing cytomegalovirus (CMV) |
| Contact |
Michael Cornish, Ph.D., Jules Stein Eye Institute-UCLA, (310) 794-5608 |
| ACTG 379 |
| Meds Used |
None, this is an observational study |
| Tx History |
Must be receiving a potent antiretroviral treatment regimen for more than eight weeks prior to study entry |
| Trial Length |
48 weeks |
| Viral Load |
No requirement |
| T-Cells |
Originally below 50, but now above 100 |
| Comments |
Discontinuation of maintenance therapy for CMV retinitis after immune reconstitution by potent antiretroviral therapy. HIV infected individuals with treated and healed non-immediate sight-threatening CMV retinitis. |
| Contact |
Gil Clemente, USC, (323) 343-8284; Christine MacNaughton, UCLA, (310) 206-6414 |
| Cidofovir-Ganciclovir |
| Meds Used |
Cidofovir-Ganciclovir |
| Tx History |
Diagnosis of CMV retinitis and cannot have used cidofovir or the intraocular implant previously |
| Trial Length |
None, participants are followed for as long as they have the implant |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Randomized, multicenter trial to evaluate and compare IV cidofovir to the ganciclovir implant with oral ganciclovir to prevent vision loss. Cidofovir will be administered intravenously once weekly for two consecutive weeks and once every two weeks thereafter. |
| Contact |
Michael Cornish, Ph.D., Jules Stein Eye Institute-UCLA, (310) 794-5608 |
| HIV & Hepatitis C |
| Meds Used |
Interferon, ribavirin |
| Tx History |
Interferon naive |
| Trial Length |
72 weeks |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Study to compare the use of interferon vs. interferon with ribavirin for the treatment of Hepatitis C |
| Contact |
Connie Funk, R.N., USC, (323) 343-8282 |
| H5230018 -- VALTREX |
| Meds Used |
Valaciclovir |
| Tx History |
Must have had four or more outbreaks within the past year or prior to beginning suppressive therapy and be on stable combination antiretroviral therapy for at least 2 months |
| Trial Length |
Six months |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Phase III study to evaluate the safety and efficacy of VALTREX therapy for the suppression of ano-genital herpes simplex virus (HSV) in HIV infected individuals. Participants will receive monthly blood work including viral load testing and T-cell counts, |
| Contact |
Michael Gonzalez, Pacific Oaks Research, (310) 360-8800 |
| MAC |
| ACTG 393 |
| Meds Used |
None |
| Tx History |
Must have DMAC diagnosis and treated for at least 12 months |
| Trial Length |
Study will last for 60 weeks. |
| Viral Load |
No requirement |
| T-Cells |
>100 |
| Comments |
Study of discontinuation of maintenance therapy in individuals with disseminated Mycobacterium Avium Complex (DMAC), and currently receiving antiretroviral therapy for at least six weeks |
| Contact |
Frances Canchola, USC, (323) 343-8281 |
| ACTG 341 |
| Meds Used |
HAART |
| Tx History |
Inclusion criteria differs for each group, although all patients will be required to undergo 1-2 bone marrow biopsies |
| Trial Length |
up to 48 weeks |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Study of the natural history and pathogenesis of Mycobacterium avium Complex (MAC) and the impact of HAART on immune functions. Three groups of individuals with MAC will be evaluated, and will be reimbursed $250 per biopsy |
| Contact |
Connie Funk, R.N., B.S.N., USC, (323) 343-8282 |
| ACTG 309 |
| Meds Used |
INH, rifampin, PZA, ethambutol |
| Tx History |
Cannot have more than one week of therapy before entering the study and have a positive acid fast bacilli smear with TB cultures pending |
| Trial Length |
Eight weeks |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Study comparing how drugs against TB work in the body for people infected with both HIV and TB. Participants will receive standard therapy for TB with at least two of the following drugs, as determined by the clinician: INH, rifampin, PZA and ethambutol. |
| Contact |
Patsy Lopez, USC, (323) 343-8267 |
| Candidiasis |
| ACTG 323 |
| Meds Used |
Fluconazole |
| Tx History |
Must have had at least one or more documented episodes of oral thrush |
| Trial Length |
Two years |
| Viral Load |
No requirement |
| T-Cells |
|
| Comments |
Phase IV, randomized study of the use of fluconazole as chronic suppressive therapy versus episodic therapy in HIV-infected participants with recurrent oropharyngeal candidiasis |
| Contact |
DeAnn Diamond, R.N., USC, (323) 343-8239; Christine MacNaughton, UCLA, (310) 206-6414 |
| Dementia |
| ACTG 301 |
| Meds Used |
Oral memantine |
| Tx History |
No active OIs |
| Trial Length |
16 weeks |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Phase II, randomized, double-blind, placebo-controlled study to assess the efficacy of oral memantine as a treatment for AIDS Dementia Complex (ADC). The effects of memantine on painful peripheral neuropathy will also be studied. Memantine will be dose es |
| Contact |
Christine MacNaughton, UCLA, (310) 206-6414 |
| Central Nervous System |
| Meds Used |
None, this is an observational study |
| Tx History |
No requirement |
| Trial Length |
Five years or more |
| Viral Load |
No requirement |
| T-Cells |
|
| Comments |
Study to define the effects of HIV on the central nervous system. and will receive detailed medical and neurological testing |
| Contact |
Jacqui Pitt, R. N., Cedars Sinai, (310) 855-3755; Edward Lozano, M.D., LAC-USC Medical Center, (323) 343-8314 |
| Human Growth Hormone |
| Meds Used |
Human growth hormone |
| Tx History |
Eligible participants must have documented unintentional weight loss of more than 10 percent and have been on stable antiviral therapy regimen for more than eight weeks prior to study entry |
| Trial Length |
48 weeks |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Randomized, double-blind, placebo-controlled dose-ranging study of recombinant human growth hormone, injected subcutaneously. The primary endpoint will be at week 12, comparing a full or half dose to the placebo arm. Lean body mass changes will be evaluated. |
| Contact |
Rachel Belanger, R.N., Cedars Sinai, (310) 855-3755 |
| For Children Only |
| ACTG P1008 (New Trial) |
| Meds Used |
Observational study |
| Tx History |
Must be on PCP/MAC prophylaxis and between the ages of 2 and 21 years old |
| Trial Length |
At least 104 weeks |
| Viral Load |
No requirement |
| T-Cells |
If between 2 and 6 years old, T-cell percentage must be 25 percent or higher. If between 6 and 21 years old, T-cell percentage must be at least 20 percent or higher. Must have two T-cell counts taken at least three months apart. |
| Comments |
Observational study to determine the impact and safety of discontinuing PCP and MAC prophylaxis. Hepatitis A vaccination will be given at entry and week 24 to measure response. |
| Contact |
Sarah Fox, R.N., CHLA, (323) 669-4537 |
| ACTG 219 |
| Meds Used |
This is an observational study |
| Tx History |
Study is open to perinatally infected infants and children currently or previously enrolled in ACTG treatment protocols |
| Trial Length |
Open-ended |
| Viral Load |
No requirement |
| T-Cells |
No requirement |
| Comments |
Prospective study to identify late outcomes and consequences related to HIV disease progression in children. Participants will receive free medical testing |
| Contact |
Sarah Fox, R.N., CHLA, (323) 669-4537 |
This article was provided by AIDS Project Los Angeles. It is a part of the publication Positive Living.
Email
Print-Friendly
Glossary
